Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025

ARROWHEAD PHARMACEUTICALS, INC.

2025-Q3 EPS reported $0.17 revenue$572,976,000

Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).
Cash & securities $900.4M; credit facility $240.3M; liability from royalty sale $360.3M.
Sanofi to pay Visirna $130M upfront for Greater China license to plozasiran; up to $265M milestones.
Earned $100M milestone from Sarepta; second enrollment target for ARO-DM1 may trigger $200M by end-2025.
Plozasiran NDA accepted with PDUFA date Nov 18, 2025; Phase 3 SHASTA-3/4 and MUIR-3 fully enrolled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.